Establishment of an Early Warning Screening System for Hemophagocytic Lymphohistiocytosis: a Multi-center, Prospective Study

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY

Our three-step screening system uses commonly used clinical and laboratory parameters to effectively identify patients who may be at high risk of HLH, conduct etiology screening early for patients who meet the diagnostic criteria for HLH, and guide standardized treatment. Therefore, this study proposes to establish a highly accurate and convenient hemophagocytic early warning system to improve the early diagnosis of patients with hemophagocytic syndrome and identify suspected HLH patients early. Etiology screening is performed on patients who meet the diagnostic criteria for HLH, high-risk predisposing factors are identified, and precise treatment is guided, thereby improving the success rate of patient treatment and improving the quality of life.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

⁃ Subjects must meet all of the following criteria:

• Patients who meet the first step screening + have ≥ 3 abnormal screening indicators in the second step

• Patients who meet the first step screening + have 2 abnormal screening indicators in the second step + patients with high-risk factors for HLH, such as history of lymphoma, EBV infection, autoimmune diseases, etc

Locations
Other Locations
China
Affilitated Hospital of Xuzhou Medical University
RECRUITING
Xuzhou
Contact Information
Primary
Wei Sang, Doctor
sw1981726@126.com
13645207648
Time Frame
Start Date: 2024-05-01
Estimated Completion Date: 2026-05-01
Participants
Target number of participants: 80
Treatments
Screening patients with suspected hemophagocytic syndrome
Preliminary screening of patients with elevated ferritin and low fibrinogen, and then continue to improve triglycerides, abdominal color ultrasound and other examinations to further clarify, for some very suspicious patients, timely improve genes, NK cell activity and other tests, as soon as possible to determine whether they are patients with hemophagocytic syndrome
Sponsors
Leads: The Affiliated Hospital of Xuzhou Medical University

This content was sourced from clinicaltrials.gov